Key result
Left ventricular assist device therapy is currently the most promising treatment option for patients with end-stage heart failure after failure of medical therapy, surgery, and cardiac resynchronization.
This review highlights the evolution of mechanical circulatory support as a critical treatment modality for end-stage heart failure, emphasizing the need for structured, multidisciplinary heart failure programs.
May support LVAD referral after failed therapies; leaves open standardization of multidisciplinary HF programs.
Chronic heart failure is a major healthcare problem associated with high morbidity and mortality. Despite significant progress in treatment strategies, the prognosis of heart failure patients remains poor. The golden standard treatment for heart failure is heart transplantation after failure of medical therapy, surgery and/or cardiac resynchronisation therapy. In order to improve patients' outcome and quality of life, new emerging treatment modalities are currently being investigated, including mechanical cardiac support devices, of which the left ventricular assist device is the most promising treatment option. Structured care for heart failure patients according to the most recent international heart failure guidelines may further contribute to optimal decision-making. This article will review the conventional and novel treatment modalities of heart failure.
No takes yet. Share an insight, caveat, or question.
Haeck et al. (2011) conducted a review in End-stage heart failure. Advanced heart failure therapies (including mechanical cardiac support) was evaluated. Left ventricular assist device therapy is currently the most promising treatment option for patients with end-stage heart failure after failure of medical therapy, surgery, and cardiac resynchronization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: